These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15649668)

  • 1. A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty.
    Sutton AJ; Cooper NJ; Abrams KR; Lambert PC; Jones DR
    J Clin Epidemiol; 2005 Jan; 58(1):26-40. PubMed ID: 15649668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention.
    Thomson R; Eccles M; Wood R; Chinn DJ
    Med Decis Making; 2007; 27(4):438-47. PubMed ID: 17641140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.
    Garwood CL; Corbett TL
    Ann Pharmacother; 2008 Apr; 42(4):523-32. PubMed ID: 18334606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncertainty in the minimum event risk to justify treatment was evaluated.
    Walter SD; Sinclair JC
    J Clin Epidemiol; 2009 Aug; 62(8):816-24. PubMed ID: 19216053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
    Leey JA; McCabe S; Koch JA; Miles TP
    Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
    Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
    Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making.
    Man-Son-Hing M; Gage BF; Montgomery AA; Howitt A; Thomson R; Devereaux PJ; Protheroe J; Fahey T; Armstrong D; Laupacis A
    Med Decis Making; 2005; 25(5):548-59. PubMed ID: 16160210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel/aspirin combination therapy in high-risk atrial fibrillation patients.
    Cardiovasc J Afr; 2009; 20(3):210. PubMed ID: 19575095
    [No Abstract]   [Full Text] [Related]  

  • 13. Can continuous quality improvement be assessed using randomized trials? [see comment].
    Samsa G; Matchar D
    Health Serv Res; 2000 Aug; 35(3):687-700. PubMed ID: 10966090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trials and tribulations of non-inferiority: the ximelagatran experience.
    Kaul S; Diamond GA; Weintraub WS
    J Am Coll Cardiol; 2005 Dec; 46(11):1986-95. PubMed ID: 16325029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the risk for stroke in patients who have atrial fibrillation.
    Garcia DA; Hylek E
    Cardiol Clin; 2008 May; 26(2):267-75, vii. PubMed ID: 18406999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
    Mant JW
    Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531
    [No Abstract]   [Full Text] [Related]  

  • 17. 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation.
    Anderson N; Fuller R; Dudley N
    QJM; 2007 May; 100(5):263-9. PubMed ID: 17389657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review.
    Szucs TD; Bramkamp M
    J Thromb Haemost; 2006 Jun; 4(6):1180-5. PubMed ID: 16706956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].
    Själander A; Wallentin L; Rosenqvist M; Svensson P
    Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.